advertisement
Abstract #15684 Published in IGR 2-3
The efficacy of topical prophylactic antiglaucoma therapy in primary closed angle glaucoma in dogs: a multicenter clinical trial
Miller PE; Schmidt GM; Vainisi SJ; Swanson JF; Herrmann MKJournal of the American Animal Hospital Association 2000; 36: 431-438
The ability of either 0.5% betaxolol (one drop topically, bid; n = 31) or a combination of 0.25% demecarium bromide and a topical corticosteroid (gentamicin/betamethasone) (DB/GB; one drop of each topically, sid; n = 55) to prevent glaucoma in the fellow eye of dogs with unilateral, primary closed-angle glaucoma (PCAG) was investigated in a multicenter, open-label, clinical trial. Untreated control dogs (n = 20) developed glaucoma significantly sooner (median, eight months; p less than 0.001) than dogs treated either with DB/GB (median, 31 months) or betaxolol (median, 30.7 months). Although DB/GB and betaxolol equally delayed or prevented the onset of glaucoma in the second eye, a less frequent dosing schedule for DB/GB suggests demecarium bromide in combination with a topical corticosteroid may be preferable to betaxolol in preventing PCAG in dogs.
Dr. P.E. Miller, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706-1102, USA
Classification:
5 Experimental glaucoma; animal models
9.3 Primary angle closure glaucomas (Part of: 9 Clinical forms of glaucomas)
11.1 General management, indication (Part of: 11 Medical treatment)
